# Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

> **NCT00262483** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 12 (—)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** VX-950
- **DRUG:** ribavirin
- **DRUG:** peginterferon alfa-2a

## Key facts

- **NCT ID:** NCT00262483
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** —
- **Final completion:** 2006-04
- **Target enrollment:** 12 (—)
- **Last updated:** 2007-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00262483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00262483, "Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00262483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*